Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CR8H
|
|||
| Former ID |
DIB001304
|
|||
| Drug Name |
SYM-004
|
|||
| Synonyms |
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19] | Phase 3 | [1] | |
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [2] | ||
| Head and neck cancer [ICD-11: 2D42] | Phase 2 | [3] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [2] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1], [2], [4] | ||
| Company |
Symphogen A/S
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02083653) Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.